Arrowhead Pharmaceuticals Inc (ARWR)vsAstraZeneca PLC (AZN)
ARWR
Arrowhead Pharmaceuticals Inc
$82.85
+0.11%
HEALTHCARE · Cap: $12.02B
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 9066% more annual revenue ($61.37B vs $669.50M). AZN leads profitability with a 17.0% profit margin vs -47.8%. AZN earns a higher WallStSmart Score of 60/100 (C+).
ARWR
Avoid33
out of 100
Grade: F
AZN
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARWR.
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 171.0% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Areas to Watch
Elevated debt levels
Trading at 25.1x book value
ROE of -68.7% — below average capital efficiency
Negative free cash flow — burning cash
2.5% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ARWR
The strongest argument for ARWR centers on Revenue Growth. Revenue growth of 171.0% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bear Case : ARWR
The primary concerns for ARWR are Debt/Equity, Price/Book, Return on Equity. Debt-to-equity of 1.86 is elevated, increasing financial risk.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ARWR profiles as a hypergrowth stock while AZN is a mature play — different risk/reward profiles.
ARWR carries more volatility with a beta of 1.28 — expect wider price swings.
ARWR is growing revenue faster at 171.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 33/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arrowhead Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?